AEON 1.06 AEON Biopharma, Inc.
| Range: | 0.636-17.17 | Vol Avg: | 230532 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 0.38 | Cap: | 0.04B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jul 24 2023 | Empoloyees: | 5 | ||
| CUSIP: | 00775E102 | CIK: | 0001622667 | ISIN: | US00791X1000 | Country: | US |
| CEO: | Mr. Marc Forth | Website: | https://www.aeonbiopharma.com | ||||
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow